{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T16:59:08Z","timestamp":1767200348593,"version":"3.48.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00011-025-02073-w","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T09:46:00Z","timestamp":1756547160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A systematic review of novel Phosphodiesterase-4 inhibitors in the treatment of psoriasis"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8655-6690","authenticated-orcid":false,"given":"Amirreza","family":"Fakhri Baghdad Abad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7259-4926","authenticated-orcid":false,"given":"Nazila","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2468-9877","authenticated-orcid":false,"given":"Zahra","family":"Lotfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-8814","authenticated-orcid":false,"given":"Amirhossein","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"issue":"2","key":"2073_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","volume":"31","author":"IM Michalek","year":"2017","unstructured":"Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205\u201312.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2073_CR2","doi-asserted-by":"crossref","unstructured":"Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Identification P et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377\u201385.","DOI":"10.1038\/jid.2012.339"},{"issue":"3","key":"2073_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"19","key":"2073_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology. Clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"9997","key":"2073_CR5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983\u201394.","journal-title":"Lancet"},{"issue":"1","key":"2073_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/pharmaceutics16010111","volume":"16","author":"A Drakos","year":"2024","unstructured":"Drakos A, Torres T, Vender R. Emerging oral therapies for the treatment of psoriasis: A review of pipeline agents. Pharmaceutics. 2024;16(1):111.","journal-title":"Pharmaceutics"},{"issue":"2","key":"2073_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1164\/ajrccm.157.2.9708012","volume":"157","author":"TJ Torphy","year":"1998","unstructured":"Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med. 1998;157(2):351\u201370.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2073_CR8","volume":"5","author":"BA Fertig","year":"2018","unstructured":"Fertig BA, Baillie GS. Pde4-mediated cAMP signalling. J Cardiovasc Dev Dis. 2018;5(1): 8.","journal-title":"J Cardiovasc Dev Dis"},{"issue":"1","key":"2073_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40257-017-0302-0","volume":"19","author":"T Torres","year":"2018","unstructured":"Torres T, Puig L. Apremilast. A novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2018;19(1):23\u201332.","journal-title":"Am J Clin Dermatol"},{"issue":"Spec Feature","key":"2073_CR10","first-page":"105","volume":"8","author":"L Fala","year":"2015","unstructured":"Fala L. Otezla (Apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am Health Drug Benefits. 2015;8(Spec Feature):105\u201310.","journal-title":"Am Health Drug Benefits"},{"issue":"5","key":"2073_CR11","first-page":"1","volume":"28","author":"A O\u2019Toole","year":"2023","unstructured":"O\u2019Toole A, Gooderham M. Topical roflumilast for plaque psoriasis. Skin Therapy Lett. 2023;28(5):1\u20134.","journal-title":"Skin Therapy Lett"},{"key":"2073_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"2073_CR13","unstructured":"National Heart L, Institute B. Quality Assessment of Clinical trials. 2014."},{"key":"2073_CR14","unstructured":"National Heart L, and Blood Institute. Quality Assessment Tool for Before-After (Pre-Post) Studies With No Control Group. 2014."},{"key":"2073_CR15","unstructured":"L. National Heart aBI. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. 2014."},{"issue":"2","key":"2073_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evidence-Based Medicine. 2018;23(2):60\u20133.","journal-title":"BMJ Evidence-Based Medicine"},{"key":"2073_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100639","author":"M Gyldenl\u00f8ve","year":"2023","unstructured":"Gyldenl\u00f8ve M, Meteran H, S\u00f8rensen JA, Fage S, Yao Y, Lindhardsen J, et al. Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis\u2014a randomized controlled trial (PSORRO). Lancet Reg Health. 2023. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100639.","journal-title":"Lancet Reg Health"},{"issue":"5","key":"2073_CR18","doi-asserted-by":"publisher","first-page":"e394","DOI":"10.1111\/jdv.20343","volume":"39","author":"M Gyldenlove","year":"2025","unstructured":"Gyldenlove M, Sorensen JA, Thomsen SF, Fage S, Iversen L, Skov L, et al. Improvements in patient-reported outcomes with oral Roflumilast for psoriasis: results from a randomized controlled trial (PSORRO). J Eur Acad Dermatol Venereol. 2025;39(5):e394\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2073_CR19","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jaad.2024.01.018","volume":"90","author":"DG Saadi","year":"2024","unstructured":"Saadi DG, El-Komy MHM, Khedr H, Shawky N, Hegazy AA, Azzazi Y, et al. A randomized, controlled pilot study of oral roflumilast compared with intramuscular methotrexate for plaque and scalp psoriasis. J Am Acad Dermatol. 2024;90(5):1063\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2073_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40257-024-00897-6","volume":"26","author":"M Gyldenlove","year":"2025","unstructured":"Gyldenlove M, Nissen CV, Stave SDW, Thomsen SF, Egeberg A, Loft N. Oral roflumilast in patients with psoriasis: a real-world cohort study. Am J Clin Dermatol. 2025;26(1):147\u201350.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"2073_CR21","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1093\/ced\/llae229","volume":"49","author":"MA Lasheras-P\u00e9rez","year":"2024","unstructured":"Lasheras-P\u00e9rez MA, Pe\u00f1uelas-Leal R, Sanchez-Carazo JL, Sahuquillo-Torralba AJ, Magdaleno-Tapial J, Torres-Navarro I, et al. Treatment of palmoplantar psoriasis with oral roflumilast: a case series. Clin Exp Dermatol. 2024;49(11):1455\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"2073_CR22","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1111\/bjd.20602","volume":"185","author":"A Egeberg","year":"2021","unstructured":"Egeberg A, Meteran H, Gyldenlove M, Zachariae C. Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy. Br J Dermatol. 2021;185(6):1251\u20132.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2073_CR23","doi-asserted-by":"publisher","first-page":"e429","DOI":"10.1111\/jdv.18647","volume":"37","author":"M Gyldenlove","year":"2023","unstructured":"Gyldenlove M, Meteran H, Zachariae C, Egeberg A. Long-term clearance of severe plaque psoriasis with oral Roflumilast. J Eur Acad Dermatol Venereol. 2023;37(3):e429\u201330.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"2073_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/jdv.18812","volume":"37","author":"RB Warren","year":"2023","unstructured":"Warren RB, Strober B, Silverberg JI, Guttman E, Andres P, Felding J, et al. Oral orismilast: efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets. J Eur Acad Dermatol Venereol. 2023;37(4):711\u201320.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"2073_CR25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jaad.2023.11.005","volume":"90","author":"RB Warren","year":"2024","unstructured":"Warren RB, French LE, Blauvelt A, Langley RG, Egeberg A, Mrowietz U, et al. Orismilast in moderate-to-severe psoriasis: efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS). J Am Acad Dermatol. 2024;90(3):494\u2013503.","journal-title":"J Am Acad Dermatol"},{"key":"2073_CR26","unstructured":"NCT05268016. Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME. 3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023 [Available from: https:\/\/kommunikasjon.ntb.no\/pressemelding\/18009237\/meiji-seika-pharma-presents-positive-findings-from-phase-ii-study-of-me3183-novel-highly-potent-selective-pde4-inhibitor-in-patients-with-plaque-psoriasis-at-eadv-congress-2023?publisherId=90063"},{"issue":"2","key":"2073_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jaad.2019.06.1288","volume":"82","author":"PW Hashim","year":"2020","unstructured":"Hashim PW, Chima M, Kim HJ, Bares J, Yao CJ, Singer G, et al. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: a double-blind, randomized, vehicle-controlled trial. J Am Acad Dermatol. 2020;82(2):360\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2073_CR28","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jamadermatol.2023.4990","volume":"160","author":"LF Eichenfield","year":"2024","unstructured":"Eichenfield LF, Tarabar S, Forman S, Garcia-Bello A, Feng G, Fetterly G, et al. Efficacy and safety of PF-07038124 in patients with atopic dermatitis and plaque psoriasis: a randomized clinical trial. JAMA Dermatol. 2024;160(2):156\u201363.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"2073_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1042\/BJ20070970","volume":"408","author":"H Wang","year":"2007","unstructured":"Wang H, Peng MS, Chen Y, Geng J, Robinson H, Houslay MD, et al. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. Biochem J. 2007;408(2):193\u2013201.","journal-title":"Biochem J"},{"key":"2073_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117009","volume":"177","author":"Z Donders","year":"2024","unstructured":"Donders Z, Skorupska IJ, Willems E, Mussen F, Broeckhoven JV, Carlier A, et al. Beyond PDE4 inhibition: a comprehensive review on downstream cAMP signaling in the central nervous system. Biomed Pharmacother. 2024;177: 117009.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"2073_CR31","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1007\/s13555-023-01054-3","volume":"13","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Langley RG, Gordon KB, Silverberg JI, Eyerich K, Sommer MOA, et al. Next generation PDE4 inhibitors that selectively target PDE4B\/D subtypes: a narrative review. Dermatol Ther (Heidelb). 2023;13(12):3031\u201342.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"2073_CR32","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40268-019-00284-1","volume":"19","author":"PH Schafer","year":"2019","unstructured":"Schafer PH, Adams M, Horan G, Truzzi F, Marconi A, Pincelli C. Apremilast normalizes gene expression of inflammatory mediators in human keratinocytes and reduces Antigen-Induced atopic dermatitis in mice. Drugs R D. 2019;19(4):329\u201338.","journal-title":"Drugs R D"},{"issue":"7","key":"2073_CR33","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cellsig.2016.01.007","volume":"28","author":"PH Schafer","year":"2016","unstructured":"Schafer PH, Truzzi F, Parton A, Wu L, Kosek J, Zhang LH, et al. Phosphodiesterase 4 in inflammatory diseases: effects of Apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4\/CD271 complex. Cell Signal. 2016;28(7):753\u201363.","journal-title":"Cell Signal"},{"key":"2073_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010023","author":"EL Crowley","year":"2023","unstructured":"Crowley EL, Gooderham MJ. Phosphodiesterase-4 inhibition in the management of psoriasis. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics16010023.","journal-title":"Pharmaceutics"},{"key":"2073_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107689","volume":"151","author":"H Bhuktar","year":"2024","unstructured":"Bhuktar H, Thirupataiah B, Mounika G, Samarpita S, Rithvik A, Sasi Priya SVS, et al. Targeting next-generation PDE4 inhibitors in search of potential management of rheumatoid arthritis and psoriasis. Bioorg Chem. 2024;151: 107689.","journal-title":"Bioorg Chem"},{"issue":"5","key":"2073_CR36","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jid.2023.09.272","volume":"144","author":"K Takahashi","year":"2024","unstructured":"Takahashi K, Miyake K, Ito J, Shimamura H, Suenaga T, Karasuyama H, et al. Topical application of a PDE4 inhibitor ameliorates atopic dermatitis through Inhibition of basophil IL-4 production. J Invest Dermatol. 2024;144(5):1048\u201357. e8.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"2073_CR37","doi-asserted-by":"publisher","first-page":"e062351","DOI":"10.1136\/bmjopen-2022-062351","volume":"12","author":"N Aroonsakul","year":"2022","unstructured":"Aroonsakul N, Phinyo P, Lumkul L, Jarupanich N, Szepietowski J, Chuamanochan M, et al. Pharmacological interventions for hidradenitis suppurativa: a protocol for systematic review and network meta-analysis of randomised trials and non-randomised studies. BMJ Open. 2022;12(9):e062351.","journal-title":"BMJ Open"},{"key":"2073_CR38","doi-asserted-by":"crossref","unstructured":"Holgersen N, Nielsen VW, Ring HC, Egeberg A, Thyssen JP, Gyldenlove M et al. Evaluating oral Roflumilast in patients with hidradenitis suppurativa previously exposed to biologic treatment. J Eur Acad Dermatol Venereol. 2024.","DOI":"10.1111\/jdv.20515"},{"issue":"1","key":"2073_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/pharmaceutics17010091","volume":"17","author":"E Carmona-Rocha","year":"2025","unstructured":"Carmona-Rocha E, Rusinol L, Puig L. Exploring the therapeutic landscape: a narrative review on topical and oral phosphodiesterase-4 inhibitors in dermatology. Pharmaceutics. 2025;17(1):91.","journal-title":"Pharmaceutics"},{"key":"2073_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1021537","volume":"13","author":"Q Kang","year":"2022","unstructured":"Kang Q, Chen J-s, Yang H. Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: a systematic review and meta-analysis of randomized controlled trials. Front Immunol. 2022;13: 2022.","journal-title":"Front Immunol"},{"issue":"5","key":"2073_CR41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40259-015-0144-3","volume":"29","author":"M Gooderham","year":"2015","unstructured":"Gooderham M, Papp K. Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast. BioDrugs. 2015;29(5):327\u201339.","journal-title":"BioDrugs"},{"key":"2073_CR42","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1136","author":"MJ Gooderham","year":"2025","unstructured":"Gooderham MJ, Alonso-Llamazares J, Bagel J, Bhatia N, Bukhalo M, DuBois J, et al. Roflumilast foam, 0.3%, for psoriasis of the scalp and body: the ARRECTOR phase 3 randomized clinical trial. JAMA Dermatol. 2025. https:\/\/doi.org\/10.1001\/jamadermatol.2025.1136.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"2073_CR43","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2000073","volume":"383","author":"MG Lebwohl","year":"2020","unstructured":"Lebwohl MG, Papp KA, Gold LS, Gooderham MJ, Kircik LH, Draelos ZD, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383(3):229\u201339.","journal-title":"N Engl J Med"},{"issue":"4","key":"2073_CR44","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/jdv.18818","volume":"37","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, French LE, Warren RB, Strober B, Kjoller K, Sommer MOA, et al. Pharmacology of orismilast, a potent and selective PDE4 inhibitor. J Eur Acad Dermatol Venereol. 2023;37(4):721\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"2073_CR45","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387\u201399.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2073_CR46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and safety trial evaluating the effects of Apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37\u201349.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"2073_CR47","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2022.15632","volume":"328","author":"MG Lebwohl","year":"2022","unstructured":"Lebwohl MG, Kircik LH, Moore AY, Stein Gold L, Draelos ZD, Gooderham MJ, et al. Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials. JAMA. 2022;328(11):1073\u201384.","journal-title":"JAMA"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02073-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-025-02073-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02073-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T16:53:24Z","timestamp":1767200004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-025-02073-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2073"],"URL":"https:\/\/doi.org\/10.1007\/s00011-025-02073-w","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"type":"print","value":"1023-3830"},{"type":"electronic","value":"1420-908X"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}